Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01045044|
Recruitment Status : Withdrawn (No participants enrolled)
First Posted : January 8, 2010
Last Update Posted : April 5, 2012
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Magnetic Resonance Imaging of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Anthracycline-based Systemic Chemotherapy|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||October 2011|
|Actual Study Completion Date :||October 2011|
Breast cancer, chemotherapy
Up to 15 women with breast cancer who are to undergo systemic anthracycline based chemotherapy.
Up to 15 normal, healthy women.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01045044
|United States, Ohio|
|Medical Oncology Hematology Associates, Inc|
|Dayton, Ohio, United States, 45408|
|Innovation Center, Kettering Health Network|
|Kettering, Ohio, United States, 45429|
|Principal Investigator:||Jason Parker, PhD||Kettering Health Network|